Akouos logo
Akouos AKUS
report update icon

Quarterly report 2022-Q3
added 05-23-2026

Akouos Market Cap | AKUS

As of October 06, 2026 Akouos has a market cap of $ 488 M


Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]

Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.

This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.

Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.

Annual Market Cap Akouos

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
184 M 358 M - - - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
358 M 184 M 271 M

References

  1. Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.

Market Cap of other stocks in the Biotechnology industry

Issuer Market Cap Price % 24h Market Cap Country
89bio 89bio
ETNB
976 M - - $ 1.55 B usaUSA
Syros Pharmaceuticals Syros Pharmaceuticals
SYRS
165 M - -8.44 % $ 3.4 M usaUSA
SpringWorks Therapeutics SpringWorks Therapeutics
SWTX
4.45 B - - $ 3.48 B usaUSA
Trevena Trevena
TRVN
5.09 M - -46.58 % $ 31.8 M usaUSA
Oncorus Oncorus
ONCR
8.55 K - -8.54 % $ 3.19 M usaUSA
OncoSec Medical Incorporated OncoSec Medical Incorporated
ONCS
17.7 M - 31.87 % $ 1.61 M usaUSA
Y-mAbs Therapeutics Y-mAbs Therapeutics
YMAB
216 M - - $ 382 M usaUSA
Oncternal Therapeutics Oncternal Therapeutics
ONCT
27.3 M - -24.12 % $ 1.56 M usaUSA
Navidea Biopharmaceuticals Navidea Biopharmaceuticals
NAVB
8.96 M - -2.99 % $ 2.47 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
548 M - -0.23 % $ 916 M usaUSA
BELLUS Health BELLUS Health
BLU
1.7 B - - $ 2.47 B canadaCanada
bluebird bio bluebird bio
BLUE
3.35 M - - $ 546 M usaUSA
Intra-Cellular Therapies Intra-Cellular Therapies
ITCI
13.3 B - - $ 13.6 B usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
114 M - - $ 35.4 M usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
1.08 M - -5.16 % $ 5.39 M usaUSA
Turning Point Therapeutics Turning Point Therapeutics
TPTX
2.35 B - -0.13 % $ 3.73 B usaUSA
Epizyme Epizyme
EPZM
126 M - - $ 249 M usaUSA
Forward Pharma A/S Forward Pharma A/S
FWP
584 M - -0.75 % $ 18.7 M danmarkDanmark
Gamida Cell Ltd. Gamida Cell Ltd.
GMDA
353 M - -18.25 % $ 5.04 M israelIsrael
Regulus Therapeutics Regulus Therapeutics
RGLS
52.7 M - - $ 155 M usaUSA
Marinus Pharmaceuticals Marinus Pharmaceuticals
MRNS
497 M - - $ 29.6 M usaUSA
NeuBase Therapeutics NeuBase Therapeutics
NBSE
6.27 M - -1.56 % $ 12.3 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
5.65 B - -6.81 % $ 3.04 B usaUSA
Scopus BioPharma Scopus BioPharma
SCPS
3.8 M - -48.37 % $ 3.71 M usaUSA
scPharmaceuticals scPharmaceuticals
SCPH
210 M - - $ 218 M usaUSA
Athersys Athersys
ATHX
8.07 M - 3.77 % $ 22.4 M usaUSA
Seagen Seagen
SGEN
26.3 B - - $ 42.2 B usaUSA
Sigilon Therapeutics Sigilon Therapeutics
SGTX
39.9 M - - $ 728 M usaUSA
Rubius Therapeutics Rubius Therapeutics
RUBY
11.7 M - -33.55 % $ 7.81 M usaUSA
TRACON Pharmaceuticals TRACON Pharmaceuticals
TCON
5.89 M - -1.38 % $ 46.8 M usaUSA
Revance Therapeutics Revance Therapeutics
RVNC
479 M - - $ 309 M usaUSA
Sierra Oncology Sierra Oncology
SRRA
288 M - -0.05 % $ 1.34 B canadaCanada
Vaccinex Vaccinex
VCNX
2.96 M - -61.37 % $ 654 K usaUSA
Forma Therapeutics Holdings Forma Therapeutics Holdings
FMTX
467 M - - $ 958 M usaUSA
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
8.32 M - -9.72 % $ 5.89 M usaUSA
Blueprint Medicines Corporation Blueprint Medicines Corporation
BPMC
5.96 B - - $ 8.14 B usaUSA
Paratek Pharmaceuticals Paratek Pharmaceuticals
PRTK
81 M - - $ 121 M usaUSA
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited
ASLN
427 M - -14.27 % $ 1.7 M singaporeSingapore
Acorda Therapeutics Acorda Therapeutics
ACOR
16.7 M - -24.86 % $ 820 K usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
664 K - -11.43 % $ 502 K usaUSA
Nabriva Therapeutics plc Nabriva Therapeutics plc
NBRV
4.1 M - - $ 4.55 M irlandaIrlanda
NGM Biopharmaceuticals NGM Biopharmaceuticals
NGM
127 M - - $ 127 M usaUSA
Unity Biotechnology Unity Biotechnology
UBX
28.1 M - -33.41 % $ 3.37 M usaUSA
Aravive Aravive
ARAV
60.4 M - -13.39 % $ 1.45 M usaUSA
Titan Pharmaceuticals Titan Pharmaceuticals
TTNP
5.23 M - -3.76 % $ 3.47 M usaUSA
iTeos Therapeutics iTeos Therapeutics
ITOS
293 M - - $ 411 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
26 M - 3.16 % $ 1.9 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
269 M - - $ 2.17 B usaUSA
TCR2 Therapeutics TCR2 Therapeutics
TCRR
57.9 M - - $ 58.1 M usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
3.43 B - - $ 3.45 B usaUSA